# References:

1. Begley, C.G.and Ioannidis, J.P.A.  ‘Reproducibility in Science’, Circulation Research,116(1), pp. 116–126. doi:10.1161/circresaha.114.303819.
2. Collins, F.S. and Tabak, L.A. ‘Policy: NIH plans to enhance reproducibility’, Nature,505(7485), pp. 612–613. doi:10.1038/505612a.
3. Macleod, [M.R.et](http://m.r.et) al. ‘Biomedical research: increasing value, reducing waste’, The Lancet,383(9912), pp. 101–104. doi:10.1016/s0140-6736(13)62329-6.
4. Freedman, L.and Gibson, M. ‘The Impact of Preclinical Irreproducibility on Drug Development’, Clinical Pharmacology & Therapeutics, 97(1), pp. 16–18.doi:10.1002/cpt.9.
